Implementing a critical infectious disease protocol

Considerations for pediatric vaccine trials in developing countries

Qualified infectious disease product designation: What's to GAIN?

Navigating a dynamic study design in hepatitis B research

A major pharmaceutical company partnered with Fortrea for a Phase II platform study. The trial's dynamic study design allowed for the addition and removal of study drugs in various treatment arms and combinations.

Key challenges in pediatric vaccine trials in low- and middle- income countries

Low- and middle-income countries (LMICs) bear a disproportionate burden of infectious diseases, with 90 % of preventable cases occurring in these regions.

See how we navigated complexities in a Phase I ICU trial

Recent years have seen a growing need for advanced critical care solutions, driven by factors such as an aging population, emerging infectious diseases and increasingly complex medical interventions.

Rapid diagnostic advantages in clinical research

The COVID-19 pandemic demonstrated how lateral flow point-of-care (POC) testing can improve target population enrichment and decrease loss of patients to key analysis sets once confirmatory testing becomes available.

Leveraging Technology for Vaccine Trial Surveillance

Vaccine trial sponsors face mounting pressure to accelerate development timelines while upholding the highest standards of data quality and participant safety.

Streamlining Site Selection and Participant Compliance for Vaccine Trials 

Two critical factors can make or break a large-scale vaccine trial: site selection and participant compliance.

Agility in Action: The Key to Successful Large-Scale Vaccine Trials

Sponsors face immense pressure to deliver safe and effective vaccines quickly.

Creative problem-solving supports site recruitment in a complex sepsis study

Implementing a novel approach for recruiting a seasonal pediatric vaccine mega-trial

This case study demonstrates how Fortrea developed a novel approach to successfully delivery a large, industry-sponsored Phase III clinical trial to prevent hospitalization of infants due to a seasonal and dangerous illness.

Creating patient- and site-centric solutions for a challenging antibiotic study

A pharmaceutical company partnered with Fortrea to support their Phase 1b pharmacokinetic clinical trial of a new antibiotic candidate for life-threatening nosocomial infections, including drug-resistant infections. 

Implementing agile solutions to successfully deliver a vaccine clinical trial in China